Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2018-004725-86
    Sponsor's Protocol Code Number:PA0012
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2020-05-29
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2018-004725-86
    A.3Full title of the trial
    A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF BIMEKIZUMAB IN THE TREATMENT OF SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS
    ÉTUDE D’EXTENSION MULTICENTRIQUE EN OUVERT VISANT A EVALUER L’INNOCUITE, LA TOLERANCE ET L’EFFICACITE A LONG TERME DU BIMEKIZUMAB DANS LE TRAITEMENT DES PATIENTS ATTEINTS DE RHUMATISME PSORIASIQUE ACTIF
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to assess the long-term safety, tolerability, and efficacy of bimekizumab in the treatment of subjects with active psoriatic arthritis
    ÉTUDE VISANT A EVALUER L’INNOCUITE, LA TOLERANCE ET L’EFFICACITE A LONG TERME DU BIMEKIZUMAB DANS LE TRAITEMENT DES PATIENTS ATTEINTS DE RHUMATISME PSORIASIQUE ACTIF
    A.3.2Name or abbreviated title of the trial where available
    BE VITAL
    A.4.1Sponsor's protocol code numberPA0012
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUCB Biopharma SRL
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUCB Biopharma SRL
    B.4.2CountryBelgium
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUCB BIOSCIENCES GmbH
    B.5.2Functional name of contact pointClin Trial Reg & Results Disclosure
    B.5.3 Address:
    B.5.3.1Street AddressAlfred-Nobel-Strasse 10
    B.5.3.2Town/ cityMonheim
    B.5.3.3Post code40789
    B.5.3.4CountryGermany
    B.5.6E-mailclinicaltrials@ucb.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBimekizumab
    D.3.2Product code UCB4940
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBIMEKIZUMAB
    D.3.9.1CAS number 1418205-77-2
    D.3.9.2Current sponsor codeUCB4940
    D.3.9.4EV Substance CodeSUB182636
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number160
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Psoriatic Arthritis
    rhumatisme psoriasique
    E.1.1.1Medical condition in easily understood language
    Psoriatic arthritis is a type of inflammatory arthritis that can cause swelling, stiffness and pain in the joints.
    Le rhumatisme psoriasique est une forme d'arthrite inflammatoire qui peut causer un gonflement, une raideur ou une douleur au niveau des
    articulations.
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level LLT
    E.1.2Classification code 10037160
    E.1.2Term Psoriatic arthritis
    E.1.2System Organ Class 100000004859
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Assess the long-term safety and tolerability of bimekizumab administered subcutaneously (sc) in adult subjects with psoriatic arthritis (PsA)
    Evaluer l'innocuité et la tolérance à long terme du bimekizumab administré par voie sous-cutanée chez des patients adultes atteints de rhumatisme psoriasique (RPs)
    E.2.2Secondary objectives of the trial
    Assess the long-term efficacy of bimekizumab
    Evaluer l'efficacité à long terme du bimekizumab
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    There will be a substudy within PA0012, DV0004 (conducted under a separate protocol), in which a subset of PA0012 subjects will be asked to participate after providing informed consent. DV0004 will evaluate the safe and effective use of self-injecting device presentations (ie, prefilled safety syringe and auto-injector presentations) for subcutaneous (sc) self-injection of bimekizumab by subjects with psoriatic arthritis (PsA) at selected sites.
    E.3Principal inclusion criteria
    -In the opinion of the Investigator, the subject is expected to benefit from participation in this Open-Label Extension study
    -Subject completed PA0010 or PA0011 without meeting any withdrawal criteria
    -Female subjects must be postmenopausal, permanently sterilized or willing to use a highly effective method of contraception
    -De l’avis de l’investigateur, le patient devrait obtenir un effet bénéfique de sa participation à cette étude d’extension en ouvert
    -Le patient a terminé l’étude PA0010 ou PA0011 sans répondre à aucun des critères d’arrêt
    -Les patientes doivent être ménopausées, stérilisées de manière définitive ou elles doivent être prêtes à utiliser une méthode de contraception très efficace
    E.4Principal exclusion criteria
    -Female subjects who plan to become pregnant during the study or within 20 weeks following the last dose of investigational medicinal product (IMP).
    -Subjects who meet any withdrawal criteria in PA0010 or PA0011. For any subject with an ongoing serious adverse event (SAE), or a history of serious infections (including hospitalizations) in the feeder studies, the Medical Monitor must be consulted prior to the subject’s entry into PA0012, although the decision to enroll the subject remains with the Investigator
    -Subject has a positive or 2 indeterminate interferon gamma release assays (IGRAs) in one of the feeder studies, unless appropriately evaluated and treated
    -Femmes prévoyant de débuter une grossesse pendant l'étude ou dans les 20 semaines suivant la dernière dose du ME
    -Patients répondant à l’un des critères d’arrêt de l’étude PA0010 ou PA0011. Pour tout patient présentant un EIG en cours ou ayant des antécédents d'infections graves (y compris des hospitalisations) dans les études préliminaires, le moniteur médical doit être consulté avant l'entrée du patient dans l’étude PA0012, même si la décision d'inclure le patient revient à l’investigateur
    -Le patient présente un résultat positif ou 2 résultats indéterminés du test IGRA dans l'une des études préliminaires, à moins qu'il ne soit évalué et traité de manière appropriée.
    E.5 End points
    E.5.1Primary end point(s)
    1. Incidence of treatment-emergent adverse events (TEAEs) during the study
    2. Incidence of serious adverse events (SAEs) during the study
    1. l’incidence des évènements indésirables apparus sous traitement (EIAT)
    2. l’incidence des évènements graves indésirables (EIG) durant l'étude
    E.5.1.1Timepoint(s) of evaluation of this end point
    From PA0012 Entry Visit until Safety Follow-Up (up to Week 160)
    De la visite de l'entrée de l'étude jusqu'à la visite de suivi (jusqu'à semaine 160)
    E.5.2Secondary end point(s)
    1. Adverse events (AEs) leading to withdrawal from investigational medicinal product (IMP) during the study
    2. American College of Rheumatology 20% improvement (ACR20) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011
    3. American College of Rheumatology 20% improvement (ACR20) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011
    4. American College of Rheumatology 20% improvement (ACR20) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011
    5. American College of Rheumatology 50% improvement (ACR50) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011
    6. American College of Rheumatology 50% improvement (ACR50) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011
    7. American College of Rheumatology 50% improvement (ACR50) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011
    8. American College of Rheumatology 70% improvement (ACR70) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011
    9. American College of Rheumatology 70% improvement (ACR70) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011
    10. American College of Rheumatology 70% improvement (ACR70) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011
    11. Psoriasis Area Severity Index 75 (PASI75) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011
    12. Psoriasis Area Severity Index 75 (PASI75) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011
    13. Psoriasis Area Severity Index 75 (PASI75) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011
    14. Psoriasis Area Severity Index 90 (PASI90) response at Week 24 in PA0012 using the Baseline of PA0010 or PA0011
    15. Psoriasis Area Severity Index 90 (PASI90) response at Week 52 in PA0012 using the Baseline of PA0010 or PA0011
    16. Psoriasis Area Severity Index 90 (PASI90) response at Week 140 in PA0012 using the Baseline of PA0010 or PA0011
    17. Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) AND at least a 2-grade reduction at Week 24 from the Baseline of PA0010 or PA0011
    18. Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) AND at least a 2-grade reduction at Week 52 from the Baseline of PA0010 or PA0011
    19. Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) AND at least a 2-grade reduction at Week 140 from the Baseline of PA0010 or PA0011
    20. Enthesitis-free state based on the Leeds Enthesitis Index (LEI) at Week 24 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011
    21. Enthesitis-free state based on the Leeds Enthesitis Index (LEI) at Week 52 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011
    22. Enthesitis-free state based on the Leeds Enthesitis Index (LEI) at Week 140 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011
    23. Enthesitis-free state based on the Spondyloarthritis Research Consortium of Canada (SPARCC) index at Week 24 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011
    24. Enthesitis-free state based on the Spondyloarthritis Research Consortium of Canada (SPARCC) index at Week 52 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011
    25. Enthesitis-free state based on the Spondyloarthritis Research Consortium of Canada (SPARCC) index at Week 140 in PA0012 using the subgroup of subjects with enthesitis at the Baseline of PA0010 or PA0011
    26. Dactylitis-free state based on the Leeds Dactylitis Index (LDI) at Week 24 in PA0012 using the subgroup of subjects with dactylitis at the Baseline of PA0010 or PA0011
    27. Dactylitis-free state based on the Leeds Dactylitis Index (LDI) at Week 52 in PA0012 using the subgroup of subjects with dactylitis at the Baseline of PA0010 or PA0011
    28. Dactylitis-free state based on the Leeds Dactylitis Index (LDI) at Week 140 in PA0012 using the subgroup of subjects with dactylitis at the Baseline of PA0010 or PA0011
    1.Evénements indésirables (EIs) entrainant un arrêt du médicament experimental (ME) durant l'étude
    2.Réponse ACR20 à la semaine 24 dans l'étude PA0012 par rapport à l’inclusion dans PA0010 ou PA0011
    3.Réponse ACR20 à la semaine 52 dans l'étude PA0012 par rapport à l’inclusion dans PA0010 ou PA0011
    4.Réponse ACR20 à la semaine 140 dans l'étude PA0012 par rapport à l’inclusion dans PA0010 ou PA0011
    5.Réponse ACR50 à la semaine 24 dans l'étude PA0012 par rapport à l’inclusion dans PA0010 ou PA0011
    6.Réponse ACR50 à la semaine 52 dans l'étude PA0012 par rapport à l’inclusion dans PA0010 ou PA0011
    7.Réponse ACR50 à la semaine 140 dans l'étude PA0012 par rapport à l’inclusion dans PA0010 ou PA0011
    8.Réponse ACR70 à la semaine 24 par rapport à l’inclusion dans PA0010 ou PA0011
    9.Réponse ACR70 à la semaine 52 dans l'étude PA0012 par rapport à l’inclusion dans PA0010 ou PA0011
    10.Réponse ACR70 à la semaine 140 dans l'étude PA0012 par rapport à l’inclusion dans PA0010 ou PA0011
    11.Réponse PASI75 à la semaine 24 dans l'étude PA0012 par rapport à l'inclusion dans PA0010 ou PA0011
    12.Réponse PASI75 à la semaine 52 dans l'étude PA0012 par rapport à l'inclusion dans PA0010 ou PA0011
    13.Réponse PASI75 à la semaine 140 dans l'étude PA0012 par rapport à l'inclusion dans PA0010 ou PA0011
    14.Réponse PASI90 à la semaine 24 dans l'étude PA0012 par rapport à l'inclusion dans PA0010 ou PA0011
    15.Réponse PASI90 à la semaine 52 dans l'étude PA0012 par rapport à l'inclusion dans PA0010 ou PA0011
    16.Réponse PASI90 à la semaine 140 dans l'étude PA0012 par rapport à l'inclusion dans PA0010 ou PA0011
    17. Score IGA de 0 (clair) ou 1 (presque clair) ET réduction d’au moins 2 grades à la semaine 24 par rapport à l’inclusion dans PA0010 ou PA0011
    18. Score IGA de 0 (clair) ou 1 (presque clair) ET réduction d’au moins 2 grades à la semaine 52 par rapport à l’inclusion dans PA0010 ou PA0011
    19. Score IGA de 0 (clair) ou 1 (presque clair) ET réduction d’au moins 2 grades à la semaine 140 par rapport à l’inclusion dans PA0010 ou PA0011
    20. LEI à la semaine 24 dans PA0012 par rapport au sous-groupe de patients avec enthésite à l’inclusion dans PA0010 ou PA0011
    21. LEI à la semaine 52 dans PA0012 par rapport au sous-groupe de patients avec enthésite à l’inclusion dans PA0010 ou PA0011
    22. LEI à la semaine 140 dans PA0012 par rapport au sous-groupe de patients avec enthésite à l’inclusion dans PA0010 ou PA0011
    23. SPARCC à la semaine 24 dans PA0012 par rapport au sous-groupe de patients avec enthésite à l’inclusion dans PA0010 ou PA0011
    24. SPARCC à la semaine 52 dans PA0012 par rapport au sous-groupe de patients avec enthésite à l’inclusion dans PA0010 ou PA0011
    25. SPARCC à la semaine 140 dans PA0012 par rapport au sous-groupe de patients avec enthésite à l’inclusion dans PA0010 ou PA0011
    26. LDI à la semaine 24 dans PA0012 par rapport au sous-groupe de patients avec dactylite à l’inclusion dans PA0010 ou PA0011
    27. LDI à la semaine 52 dans PA0012 par rapport au sous-groupe de patients avec dactylite à l’inclusion dans PA0010 ou PA0011
    28. LDI à la semaine 140 dans PA0012 par rapport au sous-groupe de patients avec dactylite à l’inclusion dans PA0010 ou PA0011
    E.5.2.1Timepoint(s) of evaluation of this end point
    1. From PA0012 Entry Visit until Safety Follow-Up (up to Week 160)
    2.; 5.; 8.; 11.; 14.; 17.; 20.; 23. and 26. Baseline of PA0010 or PA0011, Week 24 in PA0012
    3.; 6.; 9.; 12.; 15.; 18.; 21.; 24. and 27. Baseline of PA0010 or PA0011, Week 52 in PA0012
    4.; 7.; 10.; 13.; 16.; 19.; 22.; 25. and 28. Baseline of PA0010 or PA0011, Week 140 in PA0012
    1. De l'inclusion dans PA0012 jusqu'au suivi de tolérance (jusqu'à semaine 160)
    2.; 5.; 8.; 11.; 14.; 17.; 20.; 23. and 26. à l'inclusion dans PA0010 ou PA0011, Semaine 24 dans PA0012
    3.; 6.; 9.; 12.; 15.; 18.; 21.; 24. and 27. à l'inclusion dans PA0010 ou PA0011, Semaine 52 dans PA0012
    .; 7.; 10.; 13.; 16.; 19.; 22.; 25. and 28. à l'inclusion dans PA0010 ou PA0011, Semaine 140 dans PA0012
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Immunogenicity, Tolerability
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA122
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    Canada
    Czech Republic
    France
    Germany
    Hungary
    Italy
    Japan
    Poland
    Russian Federation
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months2
    E.8.9.1In the Member State concerned days14
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months6
    E.8.9.2In all countries concerned by the trial days11
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 947
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 98
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state25
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 603
    F.4.2.2In the whole clinical trial 1045
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-07-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-11-02
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 05:52:55 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA